AKBA - アケビア・セラピュ―ティクス (Akebia Therapeutics Inc.) アケビア・セラピュ―ティクス

 AKBAのチャート


 AKBAの企業情報

symbol AKBA
会社名 Akebia Therapeutics Inc (アケビア・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アケビ・セェラァピュゥーティィクス(Akebia Therapeutics Inc.)はバイオ医薬品企業である。同社は低酸素誘導性因子(HIF)の生物学に基づいた治療薬の開発と商品化に従事する。同社の主力な候補製品のバダデュスタットは、慢性腎疾患(CKD)における貧血の治療に適応される。同社は経口療法におけるバダダスタットの開発を行う。バダスタットは、CKDの貧血の治療のためのフェーズⅢ開発におけるHIF-プロリルヒドロキシラーゼ(HIF-PH)阻害剤である。また、同社は疾患を標的とするHIFベースの候補製品のポートフォリオの開発に従事する。同社のポートフォリオは、社内で開発された候補製品のAKB-6899、ライセンス取得済みの候補製品のAKB-5169を含む。AKB-5169は、炎症性腸疾患(IBD)のための経口治療として開発中の前臨床化合物である。   アケビア・セラピュ―ティクスは米国のバイオ医薬品会社。低酸素誘導因子、HIF、生物学と腎臓病の患者用製品の商品化に基づく独自の治療法の開発に焦点を当てる。 「HIF」は体内で赤血球の生産と貧血を治療する。「AKB-6548」は一日一回の経口療法、「AKB-6548」は安定的にヘモグロビンレベルを上昇させる。本社はマサチュ―セッツ州ケンブリッジ。   
本社所在地 245 First Street Suite 1100 Cambridge MA 02142 USA
代表者氏名 Muneer A. Satter ムネア・サッター
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-871-2098
設立年月日 39114
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 114人
url www.akebia.com
nasdaq_url https://www.nasdaq.com/symbol/akba
adr_tso
EBITDA EBITDA(百万ドル) -72.19200
終値(lastsale) 8.59
時価総額(marketcap) 490029976.17
時価総額 時価総額(百万ドル) 484.88320
売上高 売上高(百万ドル) 223.32200
企業価値(EV) 企業価値(EV)(百万ドル) 82.76020
当期純利益 当期純利益(百万ドル) -68.34100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Akebia Therapeutics Inc revenues increased 92% to $94.7M. Net loss decreased 13% to $57.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in R&D decrease of 72% to $1.4M (expense) Interest income increase from $1M to $2.6M (income) Other Non Rec.

 AKBAのテクニカル分析


 AKBAのニュース

   AkebiaShares Program: Current Approaches for Managing Hyperphosphatemia and Caring for Patients via Telehealth  2020/12/09 13:00:00 PR Newswire
CAMBRIDGE, Mass., Dec. 9, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the latest scheduled program of AkebiaShares, a peer-to-peer educational series…
   Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  2020/12/02 21:05:00 PR Newswire
CAMBRIDGE, Mass., Dec. 2, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 7 newly-hired employees options to purchase an aggregate of 49,000 shares of Akebia's…
   Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference  2020/11/24 13:00:00 PR Newswire
CAMBRIDGE, Mass., Nov. 24, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will participate in the Piper Sandler 32nd Annual Virtual Healthcare…
   Ex-Akebia, Merrimack employees' insider trading convictions stand  2020/11/21 00:48:47 Reuters
The 1st U.S. Circuit Court of Appeals on Friday upheld the convictions and prison sentences of former Akebia Therapeutics Inc and Merrimack Pharmaceuticals Inc employees who were found to have taken part in an insider trading scheme.
   Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™  2020/11/18 14:37:00 PR Newswire
CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked number 10 on Deloitte's Technology Fast 500™, a ranking of the…
   AkebiaShares Program: Current Approaches for Managing Hyperphosphatemia and Caring for Patients via Telehealth  2020/12/09 13:00:00 PR Newswire
CAMBRIDGE, Mass., Dec. 9, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the latest scheduled program of AkebiaShares, a peer-to-peer educational series…
   Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  2020/12/02 21:05:00 PR Newswire
CAMBRIDGE, Mass., Dec. 2, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 7 newly-hired employees options to purchase an aggregate of 49,000 shares of Akebia's…
   Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference  2020/11/24 13:00:00 PR Newswire
CAMBRIDGE, Mass., Nov. 24, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will participate in the Piper Sandler 32nd Annual Virtual Healthcare…
   Ex-Akebia, Merrimack employees' insider trading convictions stand  2020/11/21 00:48:47 Reuters
The 1st U.S. Circuit Court of Appeals on Friday upheld the convictions and prison sentences of former Akebia Therapeutics Inc and Merrimack Pharmaceuticals Inc employees who were found to have taken part in an insider trading scheme.
   Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™  2020/11/18 14:37:00 PR Newswire
CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked number 10 on Deloitte's Technology Fast 500™, a ranking of the…
   Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights  2020/10/26 12:00:00 PR Newswire
CAMBRIDGE, Mass., Oct. 26, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the third quarter ended September 30,…
   Akebia Presents Results from its PRO2TECT Global Phase 3 Program of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients Not on Dialysis During Late-Breaking Session at American Society of Nephrology Kidney Week 2020 Reimagined  2020/10/23 15:15:00 PR Newswire
/PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced the presentation of clinical data from its PRO2TECT global Phase 3 program that…
   Akebia Therapeutics (NASDAQ:AKBA) Trading Down 7.8%  2020/10/23 14:17:33 Dakota Financial News
Akebia Therapeutics Inc (NASDAQ:AKBA) was down 7.8% on Wednesday . The stock traded as low as $3.29 and last traded at $3.30. Approximately 4,452,880 shares were traded during trading, an increase of 47% from the average daily volume of 3,024,689 shares. The stock had previously closed at $3.58. Several equities analysts have recently weighed in […]
   The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO  2020/10/23 11:26:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Beam Therapeutics Inc (NASDAQ: BEAM ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunomedics, Inc. (NASDAQ: IMMU ) Kodiak Sciences Inc (NASDAQ: KOD ) Nevro Corp (NYSE: NVRO ) Praxis Precision Medicines Inc (NASDAQ: PRAX ) Repligen Corporation (NASDAQ: RGEN ) Replimune Group Inc (NASDAQ: REPL ) (priced its common stock offering of 4.69 million shares at $40 apiece. Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 22) Artelo Biosciences Inc (NASDAQ: ARTL ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Aziyo Biologics Inc (NASDAQ: AZYO ) DBV Technologies ADR Representing 0.5 Ord Shs (NASDAQ: DBVT ) FSD Pharma Inc (NASDAQ: HUGE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its $15 million worth of common stock offering) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Metacrine Inc (NASDAQ: MTCR ) Rockwell Medical Inc (NASDAQ: RMTI ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) Stocks In Focus Akebia Presents Positive Phase 3 Data For Anemia Drug In Chronic Kidney Disease Patients Akebia Therapeutics Inc (NASDAQ: AKBA ) presented at the American Society of Nephrology Kidney Week 2020 Reimagined, …
   Akebia Presents Results from its INNO2VATE Global Phase 3 Program; Demonstrated Efficacy and Cardiovascular Safety of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis  2020/10/22 21:05:00 PR Newswire
CAMBRIDGE, Mass., Oct. 22, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced the presentation of clinical data from its global INNO2VATE Phase 3 program, which demonstrated the efficacy and cardiovascular safety of vadadustat for the treatment of anemia due to…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アケビア・セラピュ―ティクス AKBA Akebia Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)